ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Pharmacological activation of dopamine receptor D1 attenuates TGF-β-induced epithelial-mesenchymal transition in A549 and BEAS-2B cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant epithelial remodeling is implicated in idiopathic pulmonary fibrosis, and TGF-β-induced epithelial-mesenchymal transition (EMT)-like changes provide an in vitro model for studying this process. This study investigated whether pharmacological stimulation of dopamine receptor D1 (DRD1) attenuates TGF-β-induced EMT-related changes in A549 and BEAS-2B cells. GEO transcriptomic analysis was performed using GSE277168 to explore TGF-β-associated transcriptional changes in A549 cells. A549 and BEAS-2B cells were stimulated with TGF-β to establish an in vitro EMT model. Dopamine analogues, DRD1 agonists, and the DRD1 antagonist SCH23390 were used to evaluate the role of DRD1. Cell viability, EMT marker expression, intracellular cAMP levels, PKA phosphorylation, migration, and adhesion were assessed. Bioinformatic analysis showed that TGF-β treatment induced EMT-, extracellular matrix-, and cAMP/PKA-related transcriptional alterations. In vitro, TGF-β reduced E-cadherin and increased Vimentin, ZEB1, and Snail1 expression. Treatment with DRD1 agonists partially attenuated these marker changes, was associated with restoration of intracellular cAMP levels and PKA phosphorylation, reduced cell migration, and increased cell adhesion. The DRD1 antagonist SCH23390 weakened the effects of DOPA treatment. In these pulmonary epithelial cell-line models, DRD1 agonist treatment attenuated TGF-β-induced EMT-related changes and was associated with restoration of cAMP/PKA signaling. These in vitro findings identify DRD1 signaling as a candidate mechanism for further preclinical study; confirmation in primary cells, epithelial-fibroblast systems, and animal models is required before therapeutic relevance to pulmonary fibrosis can be inferred.
Indexed as
Identifiers
42711392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.